NCT03745430 - RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

June 17, 2022

Study Completion Date

April 23, 2023

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

Ramucirumab

8 mg/kg (days 1 and 15, q4w) until disease progression

Trial Locations (13)

Agios Savvas Anticancer Hospital, Athens

Aretaieio Hospital, Athens

"Haematology- Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens Alexandra", Athens

"Attikon University Hospital", Chaïdári

3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens

Agii Anargiri Cancer Hospital, Athens

Ygeia Hospital, Psychikó

Metropolitan General Hospital, Cholargós

Metropolitan Hospital, Neo Faliro

University Hospital of Patra, Rio

General University Hospital of Larissa, Larissa

Department of Medical Oncology, Ioannina University Hospital, Ioannina

EUROMEDICA General Clinic of Thessaloniki, Thessaloniki